Akebia Therapeutics, Inc.

Since our founding in 2007, we’ve put tenacity and innovation to work to develop unique therapeutics that have the potential to set new standards of care for people living with kidney disease. We have emerged as a leader with deep roots in the renal community. Today, we are a fully integrated biopharmaceutical company with both an experienced nephrology-focused commercial team and a robust development organization. We have a commercial product approved and marketed in the United States, Japan and Taiwan, and a late-stage product candidate. Our lead product candidate, vadadustat, is an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI).